|
|
|
Volumn 115, Issue 4, 2002, Pages 567-570
|
|
A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients
|
|
Author keywords
Active immunotherapy; Anti idiotypic vaccine; Nasopharyngeal carcinoma
|
|
Indexed keywords
ALUMINUM HYDROXIDE;
ANTIIDIOTYPIC ANTIBODY;
CANCER VACCINE;
CYTOKINE;
GAMMA INTERFERON;
INTERLEUKIN 2;
MESSENGER RNA;
TUMOR ANTIGEN;
TUMOR NECROSIS FACTOR ALPHA;
ACTIVE IMMUNIZATION;
ADULT;
ANTIBODY BLOOD LEVEL;
ARTICLE;
CANCER STAGING;
CELLULAR IMMUNITY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG FORMULATION;
DRUG HYPERSENSITIVITY;
DRUG SAFETY;
ENZYME LINKED IMMUNOSORBENT ASSAY;
FEMALE;
HUMAN;
HUMAN CELL;
HUMORAL IMMUNITY;
IN SITU HYBRIDIZATION;
MALE;
MONONUCLEAR CELL;
NASOPHARYNX CARCINOMA;
PRECIPITATION;
PRURITUS;
ADULT;
ANTIBODIES, ANTI-IDIOTYPIC;
ANTIBODY SPECIFICITY;
CANCER VACCINES;
ENZYME-LINKED IMMUNOSORBENT ASSAY;
FEMALE;
GENE EXPRESSION REGULATION, NEOPLASTIC;
HUMANS;
IMMUNOTHERAPY, ACTIVE;
INTERFERON TYPE II;
INTERLEUKIN-2;
MALE;
MIDDLE AGED;
NASOPHARYNGEAL NEOPLASMS;
RNA, MESSENGER;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0036105713
PISSN: 03666999
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (10)
|
|
References (12)
|
